What is the purpose of this study?Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA.

What is the purpose of this study?This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).

The purpose of this research is to learn more about how the levels of different lipids affect kids with asthma and obesity. We're especially interested in how it affects kids with certain characteristics or types of asthma. In the long term, we hope this will help us understand if taking algae oil (high in certain types of lipids) might help some kids with asthma control their symptoms and reduce inflammation in their lungs.

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials OfficeEmail: iutrials@iu.eduPhone: (317) 278-5632

The primary objectives of the dose- and regimen-finding part of this study are the following: To evaluate the safety and tolerability of WTX-330 administered using a fixed dose regimen or a step-up dose regimen To determine the maximum initial dose of WTX-330 that may be used in the step-up dose regimen To determine whether the step-up dose regimen can increase WTX-330 exposure in patients due to improved tolerability To determine the maximum tolerated dose (MTD) of WTX-330 and/or recommended dose for expansion (RDE) for each regimenThe primary objectives of the dose expansion part of this study are the following: To further characterize the safety and tolerability of WTX-330 To evaluate the antitumor activity of WTX-330 as measured by overall response rate (ORR; complete response [CR] + partial response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, immune ORR (immune-ORR [iORR]; immune CR [iCR] + immune PR [iPR]) by immune RECIST (iRECIST), or Lugano classification (Cheson et al., 2014) for non-Hodgkin lymphoma (NHL)The secondary objectives of WTX-330x2102 (both parts of study) are the following: To characterize the PK profile of WTX-330 (i.e., both parent compound and free IL-12) To characterize the IFNγ profile after treatment with WTX-330 To evaluate changes in immunological biomarkers in blood samples and tumor biopsies at baseline and after administration of WTX-330 To evaluate the antitumor activity of WTX-330 as measured by duration of response (DOR) and progression-free survival (PFS) by RECIST 1.1, iRECIST, or Lugano classification (Cheson et al., 2014) for NHL. To evaluate the immunogenicity of WTX-330 (i.e., the potential to generate an antidrug antibody [ADA] responseThe secondary objectives of WTX-330x2102 (dose expansion only) are the following: To determine the impact of WTX-330 on overall survival (OS)Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632